MetaCap

ArriVent BioPharma Inc. Company Profile

NASDAQ: AVBPHealth CareBiotechnology: Pharmaceutical PreparationsUSD

10.52-0.74 (-6.57%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

ArriVent BioPharma at a glance

ArriVent BioPharma Inc. (NASDAQ: AVBP) is a Biotechnology: Pharmaceutical Preparations company in the Health Care sector headquartered in Newtown Square, PA. ArriVent BioPharma is led by Dr. Zhengbin Yao Ph.D. and employs about 77 people. The company's shares have traded publicly since 2024.

At a market capitalization of $544.1 million, it is considered a small-cap company. Its SEC Central Index Key (CIK) is 0001868279, which identifies the company's filings on EDGAR.

Summary generated from market data by MetaCap's automated system. Methodology

What does ArriVent BioPharma do?

ArriVent BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. The company's lead development candidate is firmonertinib, a tyrosine kinase inhibitor that is being evaluated in multiple clinical trials across a range of epidermal growth factor receptor mutations (EGFRm) in non-small cell lung cancer (NSCLC), including a Phase 3 clinical trial for treatment of patients with advanced or metastatic EGFRm NSCLC with exon 20 insertion mutations, as well as Phase 1b clinical trials to treat NSCLC patients with activating EGFRm, including P-loop and-alpha-c-helix compressing (PACC) mutations, and classical EGFRm NSCLC patients. It is also developing ARR-217, an antibody drug conjugate (ADC) for the treatment of gastrointestinal cancers; and ARR-002, ARR-421, and ARR-173 for solid tumors. The company has strategic collaborations with Aarvik Therapeutics Inc., Shanghai Allist Pharmaceuticals Co., Ltd., Beijing InnoCare Pharma Tech Co., Ltd., Jiangsu Alphamab Biopharmaceuticals Co., Ltd., and Lepu Biopharma Co. Ltd. ArriVent BioPharma, Inc. was incorporated in 2021 and is based in Newtown Square, Pennsylvania.

Business description based on the company's public filings.

Company information

Legal name
ArriVent BioPharma Inc.
Ticker
NASDAQ: AVBP
Industry
Biotechnology: Pharmaceutical Preparations
CEO
Dr. Zhengbin Yao Ph.D.
Employees
77
Headquarters
18 Campus Boulevard, Newtown Square, PA, United States
Phone
628 277 4836
IPO year
2024
Market cap
$544.13M
SEC CIK
0001868279
Latest annual report
10-K · Mar 5, 2026

Companies similar to ArriVent BioPharma

AVBP peer companies
CompanyPrice% ChgMarket capCompare
CBIOCrescent Biopharma Inc.13.00+0.70%$543.21Mvs AVBP
ACRSAclaris Therapeutics Inc.3.44-1.71%$545.63Mvs AVBP
CLYMClimb Bio Inc.9.19-0.97%$539.80Mvs AVBP
ANLAdlai Nortye Group Ltd. ADR8.55-5.63%$550.60Mvs AVBP
BCAXBicara Therapeutics Inc.8.44-7.46%$560.31Mvs AVBP
GERNGeron Corporation0.8707-4.63%$560.94Mvs AVBP
ZVRAZevra Therapeutics Inc.8.76-3.42%$521.26Mvs AVBP
ALMSAlumis Inc.3.96-8.54%$514.09Mvs AVBP

Related